Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Effects of Estrogen on Cognition in Girls With Turner Syndrome
This study has been completed.
Sponsored by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00001253
  Purpose

The development of the brain in females is a result of a combination of factors. During puberty estrogen plays a role in influencing brain development. Cultural and environmental factors also play a role in the development of the brain.

Female patients with Turner syndrome lack the ability to produce estrogen due to undeveloped ovaries. Therefore, Turner syndrome is the perfect condition to study how estrogen (or the lack of estrogen) influences a person's behavior and thinking.

This study will compare cognitive differences (visual motor skills, visual-spatial, psychosocial behavior, and visual memory) of patients with Turner syndrome to normal patient controls. Researchers will use the Weschler Intelligence Scale for Children-Revised (WISC-R) along with other tests and scales to measure different aspects of the patient's cognitive ability. In addition the study will review patients with Turner syndrome who previously received estrogen replacement as infants and children in a related research study.

Researchers hope to demonstrate that estrogen replacement will improve cognition and behavior in girls with Turner syndrome.


Condition Intervention Phase
Gonadal Dysgenesis
Turner's Syndrome
Behavioral: cognitive tests and scales
Phase II

Genetics Home Reference related topics: Turner syndrome
MedlinePlus related topics: Turner Syndrome
Drug Information available for: Depogen Estradiol Estradiol 3-benzoate Estradiol acetate Estradiol cypionate Estradiol dipropionate Estradiol valerate Polyestradiol phosphate Ethinyl estradiol
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Safety/Efficacy Study
Official Title: Estrogen Effects on Cognition in Girls With Turner Syndrome

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 950
Study Start Date: May 1990
Estimated Study Completion Date: March 2004
Detailed Description:

Estrogen influences brain development in females at puberty. Environmental and cultural factors interact with the biological effects of estrogen on the brain and consequently on cognition and behavior. Turner syndrome females lack endogenous estrogen as a result of dysgenetic ovaries. Turner syndrome therefore represents a unique, estrogen-deficient model in which to study the biological effects of estrogen on cognition and behavior. The specific aims of this project are to: 1) document further, the cognitive differences between girls with Turner syndrome at ages 5 to adult (less than or equal to age 50) versus age-matched, female controls. 2) to examine the differential effects of continuous estrogen replacement in infancy and in early childhood on cognitive and social function in a unique, previously approved, randomized, double-blind, placebo-controlled, treatment trial (87-CH-0152). Specifically, we hypothesize that estrogen replacement in early childhood will reduce the cognitive deficits of girls with Turner syndrome. In addition, we hypothesize that the degree of socialization ability in these girls will correlate with social-behavioral and social recognition ability. Finally, we hypothesize that earlier (infancy to 8 years) and longer estrogen replacement will result in less impairment of visual-motor ability, visual-spatial ability, socialization ability, and affective competence compared to later (9 to 12 years) estrogen replacement in girls with Turner syndrome.

Children with Turner syndrome and controls will be tested in the Outpatient Departments at the two approved sites of protocol 87-CH-0152; the NIH and Thomas Jefferson University.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

INCLUSION CRITERIA:

Patients will include girls and women ages 5-50 yr with the diagnosis of Turner syndrome based on absence of all or part of one of the X chromosomes.

Control subjects must be within +/- 2SD for height and weight and have normal intelligence and educational achievement.

Biological parents (both male and female) of TS subjects may be included in this study, but only to have blood drawn for genetic testing in order to determine the origin of the X-chromosome of their daughters.

EXCLUSION CRITERIA:

Those with severe physical or neurocognitive impairment, preventing accurate completion of the cognitive tasks, will be excluded.

Normal subjects who have qualified for or participated in gifted and talented or remedial education programs.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001253

Locations
United States, Maryland
National Institute of Child Health and Human Development (NICHD)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
Study ID Numbers: 900123, 90-CH-0123
Study First Received: November 3, 1999
Last Updated: March 3, 2008
ClinicalTrials.gov Identifier: NCT00001253  
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Turner's Syndrome
Estrogen
Ethinyl estradiol
Learning
Ovarian dysgenesis

Study placed in the following topic categories:
Chromosomal abnormalities
Genital dwarfism
Gonadal Disorders
Estradiol valerate
Chromosome Disorders
Ethinyl Estradiol
Endocrine System Diseases
Estradiol 17 beta-cypionate
Sex Differentiation Disorders
Estradiol
Monosomy X
Turner Syndrome
Gonadal dysgenesis
Urogenital Abnormalities
Genetic Diseases, Inborn
Estradiol 3-benzoate
Turner syndrome
Ovarian dwarfism
Endocrinopathy
Polyestradiol phosphate
Congenital Abnormalities
Gonadal Dysgenesis

Additional relevant MeSH terms:
Pathologic Processes
Disease
Syndrome
Sex Chromosome Disorders

ClinicalTrials.gov processed this record on January 15, 2009